Affinity Technologies, Inc.(Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced sales of its CyPath ® Lung ...
Affinity Technologies, Inc. ( ($BIAF) ) has issued an update. On October 16, 2025, bioAffinity Technologies, Inc. announced it received a ...
In 11 patients with severe cases of COPD and hypercapnic respiratory failure, lung volume reduction coil treatment was associated with significant decreases in carbon dioxide levels and improvement in ...
Affinity Technologies shares surged over 20% pre-market following a strong third-quarter sales update for its lung cancer ...
DetermaRx is the only test available today for therapeutic decisions in early stage NSCLC, addressing an estimated global market of $450M - $500M “This CMS pricing decision provides important ...
Researchers used 6MWD to assess the association between physical function and the effectiveness of ART and anti-tubercular therapy in patients with HIV/TB co-infection. In patients with TB/HIV, higher ...
Shares of Astrotech Corp. were rocketed about 6-fold (up 496%) on very heavy volume in morning trading Wednesday, after the company said it was developing a breath test that could screen for lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback